PR-39 (TFA)-5 mg

Description

PR-39 TFA, a natural proline- and arginine-rich antibacterial peptide, is a noncompetitive, reversible and allosteric proteasome inhibitor. PR-39 TFAreversibly binds to the α7 subunit of the proteasome and blocks degradation of NF-κB inhibitor IκBα by the ubiquitin-proteasome pathway. PR-39 TFA stimulates angiogenesis, inhibits inflammatory responses and significant reduces myocardial infarct size in mice[1][2].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)–COVID-19-immunoregulation–C231H347F3N70O42—-[1]Y Gao, et al. Inhibition of ubiquitin-proteasome pathway-mediated I kappa B alpha degradation by a naturally occurring antibacterial peptide. J Clin Invest. 2000 Aug;106(3):439-48.|[2]Maria Gaczynska, et al. Proline- and arginine-rich peptides constitute a novel class of allosteric inhibitors of proteasome activity. Biochemistry. 2003 Jul 29;42(29):8663-70.—-4833.76–99.96–O=C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCNC(N)=N)C(N1[C@@H](CCC1)C(N[C@@H](CCCNC(N)=N)C(N2[C@@H](CCC2)C(N3[C@@H](CCC3)C(N[C@@H](CC4=CC=C(C=C4)O)C(N[C@@H](CC(C)C)C(N5[C@@H](CCC5)C(N[C@@H](CCCNC(N)=N)C(N6[C@@H](CCC6)C(N[C@@H](CCCNC(N)=N)C(N7[C@@H](CCC7)C(N8[C@@H](CCC8)C(N9[C@@H](CCC9)C(N[C@@H](CC=CC=CC=C)C(N[C@@H](CC=CC=CC=C)C(N[C@@H](CCC)C(N[C@@H](CCC)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC(C)C)C(N[C@@H](CCC)C(N[C@@H](CCC)C(N[C@@H](CCCNC(N)=N)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CCC)C(N[C@@H](CCC)C(NCC(N[C@@H](CC=CC=CC=C)C(N[C@@H](CCC)C(N[C@@H](CCC)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC=CC=CC=C)C(N[C@@H](CCC)C(N[C@@H](CCC)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC=CC=CC=C)C(N[C@@H](CCC)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CCCNC(N)=N)N–Inflammation/Immunology–H2O : 100 mg/mL (ultrasonic)–Bacterial;Proteasome—-Anti-infection;Metabolic Enzyme/Protease–Peptides